Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Johnson and Johnson
Medtronic
McKinsey
Dow

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Asimadoline

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Asimadoline: Patents, clinical trial progress, indications

Asimadoline is an investigational drug.

There have been 7 clinical trials for Asimadoline. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2010.

The most common disease conditions in clinical trials are Syndrome, Irritable Bowel Syndrome, and Rheumatic Diseases. The leading clinical trial sponsors are Tioga Pharmaceuticals, RTI Health Solutions, and Charite University, Berlin, Germany.

There are two hundred and twenty-seven US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Asimadoline
TitleSponsorPhase
Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic DermatitisTioga PharmaceuticalsPhase 2
A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male VolunteersTioga PharmaceuticalsPhase 1
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)RTI Health SolutionsPhase 3

See all Asimadoline clinical trials

Clinical Trial Summary for Asimadoline

Top disease conditions for Asimadoline
Top clinical trial sponsors for Asimadoline

See all Asimadoline clinical trials

US Patents for Asimadoline

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Asimadoline   Start Trial Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof   Start Trial
Asimadoline   Start Trial Ultra-pure agonists of guanylate cyclase C, method of making and using same SYNERGY PHARMACEUTICALS, INC. (New York, NY)   Start Trial
Asimadoline   Start Trial Synthetic peptide amides and dimers thereof Cara Therapeutics, Inc. (Stamford, CT)   Start Trial
Asimadoline   Start Trial Formulations of guanylate cyclase C agonists and methods of use SYNERGY PHARMACEUTICALS, INC. (New York, NY)   Start Trial
Asimadoline   Start Trial Opioid agonists and uses thereof Nektar Therapeutics (San Francisco, CA)   Start Trial
Asimadoline   Start Trial 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Start Trial
Asimadoline   Start Trial Agonists of guanylate cyclase and their uses SYNERGY PHARMACEUTICALS INC. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Asimadoline

Drugname Country Document Number Estimated Expiration Related US Patent
Asimadoline European Patent Office 3324975 2035-07-22   Start Trial
Asimadoline World Intellectual Property Organization (WIPO) 2017015309 2035-07-22   Start Trial
Asimadoline Australia 2014274812 2033-06-05   Start Trial
Asimadoline Australia 2018226473 2033-06-05   Start Trial
Asimadoline Canada 2913737 2033-06-05   Start Trial
Asimadoline China 105764916 2033-06-05   Start Trial
Asimadoline Eurasian Patent Organization 201592263 2033-06-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Boehringer Ingelheim
McKesson
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.